Oxford BioMedica plc (LON:OXB)‘s stock had its “hold” rating reiterated by analysts at N+1 Singer in a research report issued on Tuesday. They presently have a GBX 3.30 ($0.04) target price on the biopharmaceutical company’s stock. N+1 Singer’s target price would indicate a potential downside of 10.81% from the company’s current price.

Separately, Jefferies Group initiated coverage on shares of Oxford BioMedica plc in a report on Friday, October 21st. They issued a “buy” rating and a GBX 8 ($0.10) price objective on the stock.

Oxford BioMedica plc (LON:OXB) opened at 3.55 on Tuesday. The company’s 50-day moving average is GBX 3.46 and its 200 day moving average is GBX 4.15. Oxford BioMedica plc has a 1-year low of GBX 2.98 and a 1-year high of GBX 8.45. The stock’s market capitalization is GBX 94.60 million.

COPYRIGHT VIOLATION WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this article can be read at http://www.dailypolitical.com/2016/11/29/oxford-biomedica-plc-oxb-receives-hold-rating-from-n1-singer.html.

In other Oxford BioMedica plc news, insider Lorenzo Tallarigo acquired 79,988 shares of the company’s stock in a transaction dated Monday, September 26th. The shares were acquired at an average cost of GBX 3 ($0.04) per share, with a total value of £2,399.64 ($2,976.85).

About Oxford BioMedica plc

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.